In patients with multiple sclerosis exacerbations, intramuscular and subcutaneous ACTH gel did not differ significantly in day 14 responder proportions.
In plain wordsIn patients with multiple sclerosis exacerbations, response rates did not differ significantly between intramuscular and subcutaneous ACTH gel.
- Peptide
- ACTH (corticotropin)
- Outcome
- No significant changePGI-C response by injection route at day 14
- Study
n = 18
- Comparator
- Subcutaneous ACTH gel
- Analysis
- Primary
- Outcome group
- Exercise and physical function · Nervous system and cognition
- Studied dose
- 80 U/day · intramuscular · five consecutive daysAs given in this study (human).
Measurements
- P value
- 0.3
- route comparison
Source sentences
The intramuscular group had numerically more responders, but there was no significant difference in the proportion of responders between the intramuscular and subcutaneous groups at day 14 (P = 0.3).
2 context sentences(design, population, supporting numbers)
At our clinic, we performed a small, prospective, randomized pilot study to examine the efficacy and safety of, and patient satisfaction with, a short (five-day) self-administered ACTH dosing protocol for exacerbations of multiple sclerosis, and to compare the subcutaneous and intramuscular routes of administration.
Each patient self-administered natural ACTH gel 80 U/day by subcutaneous or intramuscular injection for five consecutive days and was evaluated at baseline and on days 7 and 14.